It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Pill = best possible treatment course.

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Half the patients improved over baseline over 1 year.

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Anavex has over 760 patients that have taken it without any significant issues. .

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

This will bring in billions of revenue and it will make the life quality longer for AD patients.

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

CURING LEUKEMIA isn't a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

but mostly new hope for all the families and patients with AZ.

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

“We believe the use of BX1000, combined with our reversal agent, BX3000, could make for precise control of timing under neuromuscular paralysis for surgical patients, which could result in time and cost savings for patients and hospitals alike.

This could be significantly impactful for patients, surgeons, and anesthesiologists by enhancing safety, and possibly saving time and reducing costs related to delayed recovery from neuromuscular paralysis following surgical procedures.”

It's a miracle drug for patients that suffer with cronic osteoarthritis.

It is a game changer for heart patients and is being rapidly adopted by hospitals and doctors.